Pluribus Labs’s Pfizer PFE Stock Holding History

Pluribus Labs’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,935	Closed	-$255K	–	89
2022 Q1	$255K	Sell	4,935 -5,179	-51%	-$269K	1.01%	30
2021 Q4	$597K	Buy	+10,114	New	+$501K	0.63%	31

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pluribus Labs's PFE Position: Q2 2022 in Review

Pluribus Labs sold out of Pfizer (PFE) in Q2 2022, closing a stake of 4,935 shares — an estimated $255K sold.

Pluribus Labs first reported a position in PFE in Q4 2021 and held it in 2 quarters. The position peaked at $597K in Q4 2021. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.

Pluribus Labs reported no remaining Pfizer position as of Q2 2022 after selling out during the quarter.
Pluribus Labs sold 4,935 Pfizer shares in Q2 2022, an estimated $255K.
Pluribus Labs first reported a position in Pfizer in Q4 2021 and held it in 2 quarters.
Pluribus Labs's Pfizer position peaked at $597K in Q4 2021.
3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.

Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.